Rotavirus in Asia: The value of surveillance for informing decisions about the introduction of new vaccines

Journal of Infectious Diseases

Volumn 192, Issue SUPPL. 1, 2005, Pages

  Bresee, Joseph S ^a,c   Hummelman, Erik ^a   Nelson, E A S ^b   Glass, Roger I ^a  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ROTAVIRUS VACCINE;

ASIA; CLINICAL PROTOCOL; CONFERENCE PAPER; GASTROENTERITIS; HEALTH SURVEY; HOSPITALIZATION; HUMAN; PRIORITY JOURNAL; ROTAVIRUS; SOCIOECONOMICS; VIRUS INFECTION;

ASIA; CHILD, PRESCHOOL; CLINICAL TRIALS; GASTROENTERITIS; HUMANS; INFANT; POPULATION SURVEILLANCE; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINATION;

EID: 23944489394     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/431515     Document Type: Conference Paper

References (20)

1. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003; 9:565-72.
2. Miller MA, McCann L. Policy analysis of the use of hepatitis B, Haemophilus influenzae type B-, Streptococcus pneumoniae-conjugate, and rotavirus vaccines, in national immunization schedules. Health Econ 2000; 9:19-35.
3. Velazquez FR, Matson DO, Calva JJ, et al. Rotavirus infection in infants as protection against subsequent infections. N Engl J Med 1996; 335:1022-8.
4. Snyder JD, Merson MH. The magnitude of the global problem of acute diarrhoeal disease: a review of active surveillance data. Bull World Health Organ 1982; 60:605-13.
5. Kosek M, Bern C, Guerrant RL. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull World Health Organ 2003; 81:197-204.
6. The Global Alliance for Vaccines and Immunization (GAVI). Annual deaths in 2002 from diseases for which vaccines will be available soon: WHO estimates (January 2005). Available at: http://www.vaccinealliance.org/ General_Information/Immunization_informa/ Diseases_Vaccines/ vaccine_preventable_deaths .php. Geneva: GAVI Secretariat, 2005. Accessed 15 July 2005.
7. Bresee JS, Fang Z-Y, Wang B, et al. Rotavirus surveillance in Asia: first report from the "Asian Rotavirus Surveillance Network." Emerg Infect Dis 2003; 10:95-8.
8. O'Ryan M, Perez-Schael I, Mamani N, et al. Rotavirus-associated medical visits and hospitalizations in South America: a prospective study at three large sentinel hospitals. Pediatr Infect Dis J 2001; 20:685-93.
9. Steele AD, Peenze I, de Beer MC, et al. Anticipating rotavirus vaccines: epidemiology and surveillance of rotavirus in South Africa. Vaccine 2003; 21:354-60.
10. World Health Organization (WHO). Generic protocols (i) hospital-based surveillance to estimate the burden of rotavirus gastroenteritis in children and (ii) a community based survey on utilization of health care services for gastroenteritis in children. Document WHO/ V&B/02.15. Geneva: WHO, 2002:1-67.
11. Villa S, Guiscafre H, Martinez H, Munoz O, Gutierrez G. Seasonal diarrhoeal mortality among Mexican children. Bull World Health Organ 1999; 77:375-80.
12. World Health Organization (WHO). Report of the meeting on future directions for rotavirus vaccine research in developing countries. Geneva: WHO, 2000:1-56.
13. Phua KB, Quak S-H, Lee B-W, et al. Evaluation of RIX4414, a live, attenuated rotavirus vaccine, in a randomized, double-blind, placebo-controlled phase 2 trial involving 2464 Singaporean infants. J Infect Dis 2005; 192(Suppl 1): S6-16 (in this issue).
14. Heaton PM, Goveia MG, Miller JM, Offit P, Clark HF. Development of a pentavalent rotavirus vaccine against prevalent serotypes of rotavirus gastroenteritis. J Infect Dis 2005; 192(Suppl 1):S17-21 (in this issue).
15. Glass PJ, Bhan MK, Ray P, et al. Development of candidate rotavirus vaccines derived from neonatal strains in India. J Infect Dis 2005; 192(Suppl 1):S30-5 (in this issue).
16. Kapikian AZ, Simonsen L, Vesikari T, et al. A hexavalent human rotavirus-bovine rotavirus (UK) reassortant vaccine designed for use in developing countries and delivered in a schedule with the potential to eliminate the risk of intussusception. J Infect Dis 2005; 192(Suppl 1):S22-9 (in this issue).
17. Barnes GL, Lund JS, Mitchell SV, et al. Early phase II trial of human rotavirus vaccine candidate RV3. Vaccine 2002; 20:2950-6.
18. Bresee J, Glass RI, Ivanoff B, Gentsch J. Current status and future priorities for rotavirus vaccine development, evaluation, and implementation in developing countries. Vaccine 1999; 17:2207-22.
19. Del Mol P, Zissis G, Butlzler JP, Mutwewingabo A, Andre FE. Failure of live, attenuated oral rotavirus vaccine. Lancet 1980; 2:108.
20. Hanlon P, Marsh V, Shenton F, et al. Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants [letter]. Lancet 1987; 1:1342-5.